about
Prevalence of anti-RNA polymerase III antibodies in systemic sclerosis: New data from a French cohort and a systematic review and meta-analysisSpecial considerations in pregnant systemic sclerosis patients.Effect of in vitro and in vivo anakinra on cytokines production in Schnitzler syndrome.Relevance of partitioning DLCO to detect pulmonary hypertension in systemic sclerosisAn Optimized Fluorescence-Based Bidimensional Immunoproteomic Approach for Accurate Screening of Autoantibodies.B Cell Homeostasis and Functional Properties Are Altered in an Hypochlorous Acid-Induced Murine Model of Systemic Sclerosis.Survival and prognostic factors in systemic sclerosis-associated pulmonary hypertension: a systematic review and meta-analysis.Current Approaches to the Treatment of Systemic-Sclerosis-Associated Pulmonary Arterial Hypertension (SSc-PAH).Characteristics and Survival of Anti-U1 RNP Antibody-Positive Patients With Connective Tissue Disease-Associated Pulmonary Arterial Hypertension.Sweet syndrome and disseminated Mycobacterium tuberculosis infection.AB0614 Prognostic Factors of Functional Outcome in Systemic Sclerosis-Associated Interstitial Lung DiseaseSerum free light chains of immunoglobulins as biomarkers for systemic sclerosis characteristics, activity and severityEarly trajectories of skin thickening are associated with severity and mortality in systemic sclerosisClinical Characteristics and Outcome of Patients with Infective Endocarditis Diagnosed in a Department of Internal MedicinePhenotypes Determined by Cluster Analysis and Their Survival in the Prospective European Scleroderma Trials and Research Cohort of Patients With Systemic SclerosisReply
P50
Q27000819-54130ED1-583D-4BCB-8C42-EE72CC6C8972Q30244385-492E6F5C-B69E-40CE-9CD7-2018D379AD9BQ34635020-6944BA12-5CF4-4711-9C25-58DDD39B593AQ35035897-18BF2934-6BB1-4948-AD57-0422C25F6B55Q35680148-DCB98031-089C-4498-9A69-ACF7112DAC46Q37627201-F58DF685-AC2C-4321-93B7-0F54DB7DD3DAQ38112387-C58D1781-0D6D-4D75-88BD-00CA8A3AF0C8Q38721897-9A81246C-53F0-4FCE-AB4B-60F730F8D155Q40491053-63C4F821-30CE-4A30-B1FA-CA198C2270A5Q54659089-10CF0B1E-AD21-4D5A-9D99-856B8B7BE03DQ56977833-91FE6B6A-5D92-4C6D-A6B8-6BDAA7064B04Q56977854-466F9C6F-FDE4-417B-BC64-8FFBD72D6623Q89763831-33C73685-E922-4A47-B365-9C01F2BCD2E0Q91548787-DCA25725-DA7B-4359-A1F3-DAF707F4B759Q92996385-0C154F54-DA8F-46A1-A260-8299ED8DF95BQ95553742-148D3BA6-0819-4F5F-B31E-7300C6014A97
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Vincent Sobanski
@ast
Vincent Sobanski
@en
Vincent Sobanski
@es
Vincent Sobanski
@nl
type
label
Vincent Sobanski
@ast
Vincent Sobanski
@en
Vincent Sobanski
@es
Vincent Sobanski
@nl
prefLabel
Vincent Sobanski
@ast
Vincent Sobanski
@en
Vincent Sobanski
@es
Vincent Sobanski
@nl
P106
P31
P496
0000-0003-3083-2441